Blair William & CO Insmed Inc Transaction History

Blair William & CO

$33.4 Billion
Q3 2024

A detailed history of Blair William & CO transactions in Insmed Inc stock. As of the latest transaction made, Blair William & CO holds 9,091 shares of INSM stock, worth $660,642. This represents 0.0% of its overall portfolio holdings.

Number of Shares

9,091

Previous 12,863 29.32%

Holding current value

$660,642

Previous $861,000 23.0%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$62.0 - $79.01 $233,864 - $298,025	-3,772 Reduced 29.32%	9,091 $663,000
Q2 2024 Aug 12, 2024	SELL	$22.0 - $69.71 $49,192 - $155,871	-2,236 Reduced 14.81%	12,863 $861,000
Q1 2024 May 09, 2024	BUY	$25.72 - $29.94 $385 - $449	15 Added 0.1%	15,099 $409,000
Q2 2023 Aug 11, 2023	BUY	$16.44 - $21.1 $45,933 - $58,953	2,794 Added 22.73%	15,084 $318,000
Q1 2023 May 12, 2023	BUY	$16.26 - $21.73 $1,105 - $1,477	68 Added 0.56%	12,290 $209,000
Q4 2022 Feb 10, 2023	BUY	$16.98 - $23.15 $7,063 - $9,630	416 Added 3.52%	12,222 $244,000
Q3 2022 Nov 09, 2022	BUY	$20.88 - $28.21 $7,871 - $10,635	377 Added 3.3%	11,806 $254,000
Q2 2022 Aug 10, 2022	SELL	$17.07 - $25.71 $8,773 - $13,214	-514 Reduced 4.3%	11,429 $225,000
Q1 2022 May 13, 2022	SELL	$20.42 - $28.13 $64,792 - $89,256	-3,173 Reduced 20.99%	11,943 $281,000
Q4 2021 Feb 14, 2022	BUY	$25.89 - $33.45 $5,954 - $7,693	230 Added 1.55%	15,116 $412,000
Q2 2021 Aug 12, 2021	BUY	$24.17 - $36.01 $115,242 - $171,695	4,768 Added 47.12%	14,886 $424,000
Q1 2021 May 13, 2021	SELL	$32.28 - $44.3 $12,718 - $17,454	-394 Reduced 3.75%	10,118 $345,000
Q4 2020 Feb 09, 2021	BUY	$31.45 - $40.54 $330,602 - $426,156	10,512 New	10,512 $350,000

Others Institutions Holding INSM

# of Institutions

465

Shares Held

182M

Call Options Held

2.27M

Put Options Held

3.33M

View Full List

About INSMED Inc

Ticker INSM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 135,476,992
Market Cap $9.85B
Description
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversibl...

More about INSM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Blair William & CO, based on Form 13F filings with the SEC.

News

Stay updated on Blair William & CO with notifications on news.

Account